fbpx
  • Home
  • Study Details
Not currently enrolling

NEFECON for IgA Nephropathy

"This study is for patients diagnosed with Primary IgA Nephropathy, a kidney disease . it involves research and is conducted to determine the efficacy and safety of a drug called Nefecon (with the active ingredient, budesonide) The purpose of the study is to look at: • How well Nefecon works for the treatment of kidney disease and more specific for patients with the disease ""primary immunoglobulin A nephropathy"", called IgAN; and • How safe and effective Nefecon is compared to placebo."

Age & Gender

  • 18 years ~ 99 years
  • Male, Female

Contact the Team

Location

Thank you for your interest, but this study is not currently enrolling.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Amy Mottl
Medicine-Nephrology

Study Topics

Kidneys and Liver

IRB Number

18-0562

logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.